Table 3.
Base-case cost–utility results for patients with mild-to-severe primary open angle glaucoma in urban setting
| Costs per person, US$ | QALYs per person | Incremental costs per person, US$ | Incremental QALYs per person | ICURs, US$ | |
| 5 years | |||||
| MMT | 3117 | 3.14 | – | – | – |
| TRAB | 6045 | 3.33 | 2928 | 0.19 | 15 242 |
| AGV implantation | 7454 | 3.34 | 4337 | 0.20 | 21 955 |
| GATT | 8317 | 3.37 | 5200 | 0.23 | 22 400 |
| ABiC | 8920 | 3.38 | 5803 | 0.24 | 24 619 |
| 10 years | |||||
| MMT | 5761 | 5.66 | – | – | – |
| TRAB | 9196 | 5.91 | 3435 | 0.26 | 13 379 |
| AGV implantation | 10 459 | 5.95 | 4698 | 0.29 | 16 223 |
| GATT | 10 649 | 5.97 | 4888 | 0.31 | 15 675 |
| ABiC | 11 366 | 6.05 | 5605 | 0.39 | 14 203 |
Costs are given in US dollars. ICURs were calculated against maximal medical treatment. The cost-effectiveness threshold was US$30 501 per QALY gained for rural setting and US$41 568 per QALY gained for urban setting.
ABiC, ab interno canaloplasty; AGV, Ahmed glaucoma valve; GATT, gonioscopy-assisted transluminal trabeculotomy; GDP, gross domestic product; ICUR, incremental cost–utility ratio; MMT, maximal medical treatment; QALY, quality-adjusted life-year; TRAB, trabeculectomy.